Targeting long non-coding RNAs to treat triple-negative breast cancer
Development of Long non-coding RNA-directed Target Therapy for Triple-Negative Breast Cancer
['FUNDING_R01'] · UNIVERSITY OF TX MD ANDERSON CAN CTR · NIH-10796215
This study is looking at a new way to treat triple-negative breast cancer by exploring how certain RNA molecules might help us understand and improve treatments, with the hope of finding better options for patients like you.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TX MD ANDERSON CAN CTR (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-10796215 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a new treatment approach for triple-negative breast cancer (TNBC), a type of breast cancer that currently lacks effective targeted therapies. The study investigates the role of long non-coding RNAs (lncRNAs), which are regulatory RNA molecules that may influence cancer progression. By understanding how these lncRNAs affect tumor growth and immune response, researchers aim to create targeted therapies that can improve patient outcomes. The research utilizes genetically modified mouse models to explore the mechanisms by which lncRNAs contribute to TNBC and to test potential therapeutic strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with triple-negative breast cancer who have limited treatment options.
Not a fit: Patients with other types of breast cancer or those who have already received multiple lines of treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of effective targeted therapies for patients with triple-negative breast cancer.
How similar studies have performed: While the approach of targeting lncRNAs is relatively novel, there is growing interest in this area, and preliminary studies have shown promise in similar contexts.
Where this research is happening
HOUSTON, UNITED STATES
- UNIVERSITY OF TX MD ANDERSON CAN CTR — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LIN, CHUNRU — UNIVERSITY OF TX MD ANDERSON CAN CTR
- Study coordinator: LIN, CHUNRU
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Breast Cancer, Cancers, neoplasm/cancer